MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Clinical trial NCT04509791 · COMPLETED

Trial details

NCT number: NCT04509791
Sponsor: Universitaire Ziekenhuizen KU Leuven
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Diabetes Mellitus, Type 1

Start date: 2020-11-24
Primary completion: 2024-12-16
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.